Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE AND ACETAMINOPHEN vs ROGAINE EXTRA STRENGTH (FOR MEN)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full mu-opioid receptor agonist, producing analgesia via activation of descending inhibitory pathways, while acetaminophen is a centrally acting analgesic and antipyretic, likely through inhibition of cyclooxygenase (COX) in the CNS and modulation of serotonergic pathways.
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. It also prolongs the anagen phase of hair follicles and increases hair follicle size, promoting hair growth.
Management of moderate to moderately severe pain (FDA approved),Off-label: acute pain, postoperative pain
Treatment of androgenetic alopecia (male pattern baldness) in men
Oral: 5-10 mg oxycodone (with 325-650 mg acetaminophen) every 4-6 hours as needed; maximum oxycodone 60 mg/day (for immediate-release) or acetaminophen 4000 mg/day. Titrate to pain control.
1 m L of 5% minoxidil solution applied topically to the scalp twice daily.
Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release). Acetaminophen: 1.5-3 hours. Clinical context: Half-life may be prolonged in hepatic impairment, elderly, and renal failure.
Terminal elimination half-life is approximately 4.2 hours (range 3.5–5.0 hours) in healthy adults. Clinical context: Maintains steady-state concentrations with twice-daily topical application without significant accumulation.
Oxycodone is extensively metabolized in the liver via CYP3A4 (primarily) and CYP2D6 (minor) to noroxycodone, oxymorphone, and other metabolites. Acetaminophen is metabolized in the liver mainly via glucuronidation and sulfation with a minor CYP2E1 pathway producing toxic NAPQI.
Minoxidil is primarily metabolized by conjugation with glucuronic acid at the N-oxide position in the liver. CYP450 enzymes are minimally involved.
Oxycodone: renal (primarily as noroxycodone, oxymorphone, and conjugated metabolites; <10% unchanged). Acetaminophen: renal (85-90% as sulfate and glucuronide conjugates; 2-4% unchanged; 8-10% as cysteine and mercapturate conjugates). Biliary/fecal excretion: minor (<5% for both).
Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination. Fecal excretion is minimal (<3%).
Oxycodone: 38-45% (primarily to albumin). Acetaminophen: 10-25% (minimal binding).
Approximately 20% bound to plasma proteins (primarily albumin).
Oxycodone: 2.6-3.0 L/kg (wide distribution into tissues). Acetaminophen: 0.9-1.0 L/kg (uniformly distributed in body fluids).
Apparent volume of distribution is approximately 2.5 L/kg, indicating extensive distribution into total body water and tissues.
Oral immediate-release: oxycodone 60-87%, acetaminophen 68-88%. Oral extended-release: oxycodone 60-87% (less variable). Rectal: variable (unspecified for this combination).
Topical: systemic bioavailability is low (approximately 1.4% of applied dose) due to poor percutaneous absorption. Oral: approximately 50% (not indicated for this formulation).
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: acetaminophen no change, oxycodone consider 75% of usual dose; Cr Cl 10-29 m L/min: acetaminophen extend interval to q6h, oxycodone consider 50% of usual dose; Cr Cl <10 m L/min: acetaminophen avoid or 650 mg q8h, oxycodone 50% of usual dose; hemodialysis: acetaminophen 650 mg q8h, oxycodone 25-50% of usual dose.
No dosage adjustment required for renal impairment; not systemically absorbed in significant amounts.
Child-Pugh A: no adjustment; Child-Pugh B: oxycodone reduce dose by 50%, acetaminophen maximum 2000 mg/day; Child-Pugh C: oxycodone reduce dose by 75%, acetaminophen maximum 2000 mg/day; severe hepatic impairment: avoid acetaminophen component.
No dosage adjustment required for hepatic impairment; not systemically absorbed in significant amounts.
Children ≥6 months: 0.05-0.15 mg/kg oxycodone (based on oxycodone component) every 4-6 hours, maximum single dose 5 mg; acetaminophen 10-15 mg/kg/dose, maximum 75 mg/kg/day (up to 4000 mg/day). Weight-based oxycodone not to exceed adult dose.
Safety and effectiveness in pediatric patients under 18 years have not been established.
Start at 50% of adult dose (oxycodone 2.5-5 mg every 6 hours), titrate cautiously; maximum acetaminophen 3000 mg/day due to decreased hepatic reserves; monitor for renal impairment and avoid if Cr Cl <30 m L/min.
No specific dosage adjustment; use with caution due to potential for increased systemic absorption from thinner skin.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; accidental ingestion may be fatal; risk of hepatotoxicity with acetaminophen overdose.
No FDA boxed warning.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; hepatotoxicity (acetaminophen); severe hypotension; adrenal insufficiency; seizures; increased risk of overdose in patients with head injury or COPD.
Cardiovascular risks such as tachycardia, fluid retention, and pericardial effusion with topical use are rare but possible.,May cause hypotension if accidentally ingested.,Avoid contact with eyes and broken skin.,Discontinue if scalp irritation occurs.,Use with caution in patients with hypertension or underlying cardiovascular disease.
Hypersensitivity to oxycodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; known or suspected gastrointestinal obstruction; severe hepatic impairment (acetaminophen).
Hypersensitivity to minoxidil or any component of the formulation.,Concomitant use with other topical agents on the scalp.
Avoid alcohol consumption; increases risk of hepatotoxicity from acetaminophen and potentiates CNS depression. Grapefruit juice may increase oxycodone absorption; avoid concurrent use. High-fat meals can delay oxycodone peak concentration, potentially reducing rapid pain relief. No specific restrictions with other foods.
No known food interactions.
First trimester: Risk of neural tube defects not significantly increased with therapeutic use; opioid dependence may increase risk of congenital malformations (e.g., gastroschisis). Second/third trimester: Chronic use may cause fetal opioid dependence, leading to neonatal abstinence syndrome (NAS). Late third trimester: Risk of respiratory depression in neonate if used near delivery.
Topical minoxidil (Rogaine Extra Strength) is minimally absorbed (approximately 1.4% of applied dose). Animal studies show no teratogenicity at systemic exposures up to 4 times the human dose. Human data are insufficient; risk is considered low but cannot be excluded. Use only if clearly needed during pregnancy. No specific trimester risks identified.
Excreted into breast milk in low concentrations. M/P ratio for oxycodone: 3.2:1; acetaminophen: approximately 1.0. Considered compatible with breastfeeding with caution; monitor infant for sedation and feeding difficulties. Avoid if maternal codeine use due to CYP2D6 ultrarapid metabolism concerns (though oxycodone less affected).
Minoxidil is excreted in human milk following oral administration; however, following topical application, systemic absorption is minimal (1.4%). The M/P ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No standard dose adjustment required for maternal pharmacokinetic changes. Increased renal clearance in pregnancy may slightly reduce acetaminophen levels, but therapeutic effect maintained. Oxycodone metabolism via CYP3A4 and 2D6; pregnancy-induced enzyme changes may alter clearance, but clinical significance unclear. Use lowest effective dose, avoid NSAIDs if co-prescribed.
No dose adjustment is necessary. Pharmacokinetic changes in pregnancy (e.g., increased blood volume, altered skin perfusion) are not expected to significantly alter the minimal systemic absorption of topical minoxidil. Use standard dosing: 1 m L twice daily to the scalp.
Maximum daily acetaminophen dose is 4000 mg from all sources; prescribed combination tablets contribute to this limit. Oxycodone immediate-release duration is 3-6 hours; avoid crushing extended-release formulations. Both components have abuse potential; screen for opioid use disorder. In renal impairment, adjust dosing interval for oxycodone; avoid in Cr Cl <30 m L/min. In hepatic impairment, the acetaminophen component may be hepatotoxic; avoid in severe disease. Coadministration with serotonergic agents may precipitate serotonin syndrome. Naloxone is the reversal agent for oxycodone; acetylcysteine for acetaminophen overdose.
Rogaine Extra Strength (5% minoxidil) is indicated for androgenetic alopecia in men. Onset of hair regrowth typically occurs after at least 4 months of twice-daily use; continued use is required to maintain effects. Discontinue if scalp irritation or unwanted facial hair growth occurs. Not effective for receding frontal hairline; primarily promotes vertex balding. May cause initial shedding of telogen hairs, which is a sign of efficacy.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not take other products containing acetaminophen (e.g., Tylenol, cold medications) to avoid exceeding the maximum daily dose of 4000 mg.,Avoid alcohol while taking this medication; liver damage risk increases with alcohol use.,Do not crush, break, or chew tablets; swallow whole to avoid rapid release of oxycodone.,This medication can cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Store securely out of sight and reach of children; dispose of unused medication via a drug take-back program.,Take with food if nausea occurs; avoid high-fat meals as they may delay absorption.,Do not stop abruptly; withdrawal symptoms may occur. Consult your doctor for a tapering schedule.
Apply 1 m L directly to the scalp in the affected area twice daily, not more often.,Wash hands thoroughly after each application.,Do not apply to wet hair or within 24 hours of using other scalp treatments.,Results may take 4 months or longer; continued use is necessary to maintain regrowth.,Initial hair shedding is normal and indicates new hair growth.,Avoid contact with eyes; if accidental contact occurs, rinse with cool water.
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCODONE AND ACETAMINOPHEN vs ROGAINE EXTRA STRENGTH (FOR MEN), answered by our medical review team.
OXYCODONE AND ACETAMINOPHEN is a Opioid Agonist that works by Oxycodone is a full mu-opioid receptor agonist, producing analgesia via activation of descending inhibitory pathways, while acetaminophen is a centrally acting analgesic and antipyretic, likely through inhibition of cyclooxygenase (COX) in the CNS and modulation of serotonergic pathways.. ROGAINE EXTRA STRENGTH (FOR MEN) is a Hair Growth Agent that works by Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. It also prolongs the anagen phase of hair follicles and increases hair follicle size, promoting hair growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCODONE AND ACETAMINOPHEN and ROGAINE EXTRA STRENGTH (FOR MEN) depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCODONE AND ACETAMINOPHEN is: Oral: 5-10 mg oxycodone (with 325-650 mg acetaminophen) every 4-6 hours as needed; maximum oxycodone 60 mg/day (for immediate-release) or acetaminophen 4000 mg/day. Titrate to pain control.. The standard adult dose of ROGAINE EXTRA STRENGTH (FOR MEN) is: 1 m L of 5% minoxidil solution applied topically to the scalp twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCODONE AND ACETAMINOPHEN and ROGAINE EXTRA STRENGTH (FOR MEN) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCODONE AND ACETAMINOPHEN is classified as Category D/X. First trimester: Risk of neural tube defects not significantly increased with therapeutic use; opioid dependence may increase risk of congenital malformations (e.g., gastroschisis). ROGAINE EXTRA STRENGTH (FOR MEN) is classified as Category C. Topical minoxidil (Rogaine Extra Strength) is minimally absorbed (approximately 1.4% of applied dose). Animal studies show no teratogenicity at systemic exposures up to 4 times the. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.